3 Steps To Success: How Swing Therapeutics Harnessed Medrio Solutions To Secure FDA Clearance

Empowering individuals dealing with chronic pain, Swing Therapeutics has been a pioneer in prescription digital therapy. Notably, the company has recently secured De Novo marketing authorization for Stanza, which addresses fibromyalgia symptoms through a 12-week self-guided Acceptance and Commitment Therapy program. Stanza is the first of many therapies designed to cater to different conditions and is presently integrated into Swing Care, a telehealth platform offering personalized fibromyalgia treatment.

During 2021, Swing Therapeutics conducted a randomized, controlled pilot trial featuring 67 participants to assess Stanza's efficacy. This pilot study made use of Medrio's CDMS/EDC and eCOA/ePRO solutions. Learn how the therapeutic company was able to utilize these tools to enable a decentralized approach, relieve the burden on clinical sites, advocate for the collection of comprehensive and high-quality data, and successfully demonstrate safety and efficacy to regulatory authorities.